Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05555732
Registration number
NCT05555732
Ethics application status
Date submitted
22/09/2022
Date registered
27/09/2022
Date last updated
26/06/2025
Titles & IDs
Public title
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Query!
Scientific title
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Query!
Secondary ID [1]
0
0
2022-500802-16-00
Query!
Secondary ID [2]
0
0
DS1062-A-U303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Non Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Datopotamab Deruxtecan
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin
Experimental: Dato-DXd + Pembrolizumab + Platinum Chemotherapy - Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]).
Experimental: Dato-DXd + Pembrolizumab - Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab.
Active comparator: Pembrolizumab + Pemetrexed + Platinum Chemotherapy - Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]).
Treatment: Drugs: Datopotamab Deruxtecan
Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Treatment: Drugs: Pembrolizumab
Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Treatment: Drugs: Pemetrexed
Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Treatment: Drugs: Carboplatin
Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Treatment: Drugs: Cisplatin
Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival Based on Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [1]
0
0
Progression-free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.
Query!
Timepoint [1]
0
0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Query!
Primary outcome [2]
0
0
Overall Survival in Participants in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [2]
0
0
Overall Survival (OS) is defined as the time from randomization to death due to any cause.
Query!
Timepoint [2]
0
0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Query!
Secondary outcome [1]
0
0
Objective Response Rate by Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [1]
0
0
Objective Response Rate (ORR) is defined as the proportion of participants who achieved a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), assessed by BICR per RECIST Version 1.1.
Query!
Timepoint [1]
0
0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Query!
Secondary outcome [2]
0
0
Progression-free Survival by Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [2]
0
0
Progression-free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed by the Investigator per RECIST Version 1.1.
Query!
Timepoint [2]
0
0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Query!
Secondary outcome [3]
0
0
Objective Response Rate by Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [3]
0
0
Objective Response Rate (ORR) is defined as the proportion of participants who achieved a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), assessed by the Investigator per RECIST Version 1.1.
Query!
Timepoint [3]
0
0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Query!
Secondary outcome [4]
0
0
Duration of Response by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [4]
0
0
Duration of Response (DoR) is defined as the time from the date of the first documentation of objective response (confirmed CR or confirmed PR) to the date of the first radiographic disease progression or death due to any cause, whichever occurs first, assessed by BICR and by the Investigator per RECIST Version 1.1.
Query!
Timepoint [4]
0
0
From date of first objective response (CR or PR) to date of first radiographic disease progression or death due to any cause (whichever occurs first), up to approximately 29 months
Query!
Secondary outcome [5]
0
0
Time to Response by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [5]
0
0
Time to Response (TTR) is defined as the time from randomization to the date of the first documentation of objective response (confirmed CR or confirmed PR) in responding participants, assessed by BICR and by the Investigator per RECIST Version 1.1.
Query!
Timepoint [5]
0
0
From randomization to date of first objective response (CR or PR), up to approximately 29 months
Query!
Secondary outcome [6]
0
0
Disease Control Rate by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [6]
0
0
Disease Control Rate (DCR) is defined as the proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD), assessed by BICR and by the Investigator per RECIST Version 1.1.
Query!
Timepoint [6]
0
0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Query!
Secondary outcome [7]
0
0
Progression-free Survival 2 in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [7]
0
0
Progression-free Survival 2 (PFS2) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed by local standard clinical practice
Query!
Timepoint [7]
0
0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Query!
Secondary outcome [8]
0
0
Time to Deterioration in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [8]
0
0
Time to Deterioration (TTD) is defined as the time from randomization to first onset of a =10-point increase in cough, chest pain, or dyspnea, confirmed by a second adjacent =10-point increase from randomization in the same symptom, or confirmed by death within 21 days of a =10-point increase from randomization, assessed the European Organization for Research and Treatment of Cancer Lung cancer module (EORTC-QLQ-LC13).
Query!
Timepoint [8]
0
0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Query!
Secondary outcome [9]
0
0
Number of Participants With Treatment-emergent Adverse Events (TEAE) in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Query!
Assessment method [9]
0
0
A TEAE is defined as an AE with a start or worsening date on or after the start date of study treatment until 37 days after the end date of study treatment.
Query!
Timepoint [9]
0
0
Up to 57 months
Query!
Secondary outcome [10]
0
0
Proportion of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) and Proportion of Participants Who Have Treatment-emergent ADA
Query!
Assessment method [10]
0
0
The immunogenicity of Dato-DXd in combination with pembrolizumab will be assessed.
Query!
Timepoint [10]
0
0
Baseline and up to 57 months
Query!
Eligibility
Key inclusion criteria
Key
1. Sign and date the Main ICF, prior to the start of any study- specific qualification procedures. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
2. Adults =18 at the time the Main ICF is signed. (Follow local regulatory requirements if the legal age of adult voluntary consent for study participation is >18 years old).
3. Has tumor with PD-L1 TPS <50% as determined by PD-L1 IHC 22C3 pharmDx assay by central testing (minimum of six slides). PD-L1 expression results available at the same central laboratory from screening for the purpose of entry into another Dato-DXd study may be used for tissue screening purposes in this study as long as the subject has not been randomized/enrolled in the other study.
4. Has provided a formalin-fixed tumor tissue sample (minimum of 4 × 4-micron sections or block equivalent) for the measurement of TROP2 protein expression and for the assessment of other exploratory biomarkers. This tissue requirement is in addition to the tissue required for PD-L1 testing for tissue screening purposes. If a documented law or regulation prohibits (or does not approve) sample collection, then such sample will not be collected, and the subject is still eligible for the study.
5. Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Subjects who received adjuvant or neoadjuvant therapy other than those listed in the exclusion criteria are eligible if the adjuvant/ neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced/metastatic disease and should not have progressed on or within the 6 months of completion.
6. Has measurable disease based on local imaging assessment using RECIST v1.1; radiographic tumor assessment must be performed within 28 days before randomization.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Has received prior systemic treatment for advanced/metastatic NSCLC.
2. Has received prior treatment with any of the following, including in the adjuvant/neoadjuvant setting (for NSCLC):
1. Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I
2. TROP2-targeted therapy
3. Any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137)
4. Any other ICIs Subjects who received adjuvant or neoadjuvant therapy OTHER than those listed above are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced or metastatic disease.
3. Has received a live vaccine within 30 days prior to the first dose of study treatment.
Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. For any subject receiving an approved severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine, please follow the vaccine label and/or local guidance. The vaccine manufacturer and the date of administration should be recorded on the electronic case report form (Concomitant Medications page), as should any AEs relating to the vaccine (including hypersensitivity or allergies). Note: Any licensed SARS-CoV2 vaccine (including those authorized for emergency use) in a particular country is allowed in the study as long as the vaccine is an mRNA vaccine, replication-incompetent adenoviral vaccine, or inactivated vaccine. Such vaccines will be treated just as any other concomitant therapy.
Investigational vaccines (ie, those not licensed or authorized for emergency use) are not allowed.
4. Has spinal cord compression or clinically active untreated CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 2 weeks by repeat imaging (Note: Repeat imaging should be performed during study screening), clinically stable, and without requirement of steroid treatment for at least 7 days before the first dose of study drug. Note: A contrasted computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the brain at baseline (MRI with contrast preferred) is required for all subjects. For those subjects in whom CNS metastases are first discovered at the time of screening, the treating investigator must delay of study treatment to document stability of CNS metastases with repeat imaging at least 2 weeks later (in which case, repeat of all screening activity may be required).
5. Has uncontrolled or significant cardiovascular disease not controlled by maximal medical therapy, including:
1. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval >470 msec regardless of sex (based on the 12-lead electrocardiogram [ECG] performed at screening).
2. Myocardial infarction within 6 months prior to Cycle 1 Day 1.
3. History of a serious cardiac arrhythmia requiring treatment
4. Uncontrolled angina pectoris within 6 months prior to Cycle 1 Day 1.
5. Left ventricular ejection fraction (LVEF) <50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization.
6. New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF) at screening. Subjects with a history of Class II to IV CHF prior to screening, must have returned to Class I CHF and have LVEF =50% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligible.
7. Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg within 28 days before randomization that is not resolved despite maximal medical therapy).
6. Clinically severe pulmonary compromise as judged by the investigator resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli diagnosed within 3 months of Cycle 1 Day 1, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc) or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc), or prior complete pneumonectomy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/01/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/08/2027
Query!
Actual
Query!
Sample size
Target
1170
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
CRSA/ St Andrews Hospital - Adelaide
Query!
Recruitment hospital [2]
0
0
Flinders Medical Centre (Fmc) - Bedford Park
Query!
Recruitment hospital [3]
0
0
PSEHOG (Peninsula and South Eastern Haematology and Oncology Group) - Frankston
Query!
Recruitment hospital [4]
0
0
St George Public Hospital - Kogarah
Query!
Recruitment hospital [5]
0
0
Southern Medical Day Care Centre - Wollongong
Query!
Recruitment hospital [6]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [4]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [5]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [6]
0
0
QLD 4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Utah
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Washington
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Ciudad Autonoma de Buenos Aire
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Mar del Plata
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Pergamino
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Rosario
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
San Juan
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Viedma
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Feldkirch
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Klagenfurt
Query!
Country [24]
0
0
Austria
Query!
State/province [24]
0
0
Vienna
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Gent
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Haine Saint-Paul
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Hasselt
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Ottignies
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Sint-Niklaas
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Belo Horizonte
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Caxias do Sul
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Curitiba
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Ijui
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
ItajaA-
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Pelotas
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Porto Alegre
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
Rio de Janeiro
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Santo Andre
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Sao Paulo
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Taubate
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Quebec City
Query!
Country [42]
0
0
Chile
Query!
State/province [42]
0
0
Santiago de Chile
Query!
Country [43]
0
0
Chile
Query!
State/province [43]
0
0
Santiago
Query!
Country [44]
0
0
Chile
Query!
State/province [44]
0
0
Vina Del Mar
Query!
Country [45]
0
0
Chile
Query!
State/province [45]
0
0
ViAaa Del Mar
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Beijing Sheng
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Beijing
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Cangzhou
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Changchun
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Changsha
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Chengdu
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Chongqing
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Fuzhou
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Guangzhou
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Hangzhou
Query!
Country [56]
0
0
China
Query!
State/province [56]
0
0
Harbin
Query!
Country [57]
0
0
China
Query!
State/province [57]
0
0
Hohhot
Query!
Country [58]
0
0
China
Query!
State/province [58]
0
0
Jiamusi
Query!
Country [59]
0
0
China
Query!
State/province [59]
0
0
Linyi
Query!
Country [60]
0
0
China
Query!
State/province [60]
0
0
Nanchang
Query!
Country [61]
0
0
China
Query!
State/province [61]
0
0
Nanjing
Query!
Country [62]
0
0
China
Query!
State/province [62]
0
0
Shanghai
Query!
Country [63]
0
0
China
Query!
State/province [63]
0
0
Shenyang
Query!
Country [64]
0
0
China
Query!
State/province [64]
0
0
Wuhan
Query!
Country [65]
0
0
China
Query!
State/province [65]
0
0
Xi'an
Query!
Country [66]
0
0
China
Query!
State/province [66]
0
0
Xianyang
Query!
Country [67]
0
0
China
Query!
State/province [67]
0
0
Zhengzhou
Query!
Country [68]
0
0
China
Query!
State/province [68]
0
0
Ürümqi
Query!
Country [69]
0
0
Czechia
Query!
State/province [69]
0
0
Brno
Query!
Country [70]
0
0
Czechia
Query!
State/province [70]
0
0
Olomouc
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Avignon
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Besancon
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Bordeaux
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
France
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Lyon
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Marseille Cedex 20
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Marseille
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Montpellier Cedex 5
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Nantes
Query!
Country [80]
0
0
France
Query!
State/province [80]
0
0
Paris Cedex 05
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
Paris
Query!
Country [82]
0
0
France
Query!
State/province [82]
0
0
Rennes
Query!
Country [83]
0
0
France
Query!
State/province [83]
0
0
Suresnes
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Berlin
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Chemnitz
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Essen
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Esslingen
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Freiburg
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Giessen
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Mannheim
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Muenster
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Munich
Query!
Country [93]
0
0
Greece
Query!
State/province [93]
0
0
Athens
Query!
Country [94]
0
0
Greece
Query!
State/province [94]
0
0
Heraklion
Query!
Country [95]
0
0
Greece
Query!
State/province [95]
0
0
Ioannina
Query!
Country [96]
0
0
Greece
Query!
State/province [96]
0
0
Neo Faliro
Query!
Country [97]
0
0
Greece
Query!
State/province [97]
0
0
Patras
Query!
Country [98]
0
0
Greece
Query!
State/province [98]
0
0
Thessaloniki
Query!
Country [99]
0
0
Greece
Query!
State/province [99]
0
0
Thessalonki
Query!
Country [100]
0
0
Hong Kong
Query!
State/province [100]
0
0
Hong Kong
Query!
Country [101]
0
0
Hong Kong
Query!
State/province [101]
0
0
Pok Fu Lam
Query!
Country [102]
0
0
Hungary
Query!
State/province [102]
0
0
Budapest
Query!
Country [103]
0
0
Hungary
Query!
State/province [103]
0
0
Farkasgyepu
Query!
Country [104]
0
0
Hungary
Query!
State/province [104]
0
0
KecskemAŠt
Query!
Country [105]
0
0
Hungary
Query!
State/province [105]
0
0
Szekesfehervar
Query!
Country [106]
0
0
Hungary
Query!
State/province [106]
0
0
Szolnok
Query!
Country [107]
0
0
Hungary
Query!
State/province [107]
0
0
Torokbalint
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Candiolo
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Lucca
Query!
Country [110]
0
0
Italy
Query!
State/province [110]
0
0
Orbassano
Query!
Country [111]
0
0
Italy
Query!
State/province [111]
0
0
Rome
Query!
Country [112]
0
0
Italy
Query!
State/province [112]
0
0
Udine
Query!
Country [113]
0
0
Italy
Query!
State/province [113]
0
0
Varese
Query!
Country [114]
0
0
Italy
Query!
State/province [114]
0
0
Verona
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Ehime
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Fukoka
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Fukuoka
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Hokkaido
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Hyogo
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Ishikawa
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Kanagawa
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Kumamoto
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Kyoto
Query!
Country [124]
0
0
Japan
Query!
State/province [124]
0
0
Mie
Query!
Country [125]
0
0
Japan
Query!
State/province [125]
0
0
Miyagi
Query!
Country [126]
0
0
Japan
Query!
State/province [126]
0
0
Niigata
Query!
Country [127]
0
0
Japan
Query!
State/province [127]
0
0
Osaka
Query!
Country [128]
0
0
Japan
Query!
State/province [128]
0
0
Tochigi
Query!
Country [129]
0
0
Japan
Query!
State/province [129]
0
0
Tokyo
Query!
Country [130]
0
0
Japan
Query!
State/province [130]
0
0
Yamaguchi
Query!
Country [131]
0
0
Japan
Query!
State/province [131]
0
0
Yamanashi
Query!
Country [132]
0
0
Korea, Republic of
Query!
State/province [132]
0
0
Cheongjusi
Query!
Country [133]
0
0
Korea, Republic of
Query!
State/province [133]
0
0
Daegu
Query!
Country [134]
0
0
Korea, Republic of
Query!
State/province [134]
0
0
Gangnam-Gu
Query!
Country [135]
0
0
Korea, Republic of
Query!
State/province [135]
0
0
Goyang-si
Query!
Country [136]
0
0
Korea, Republic of
Query!
State/province [136]
0
0
Jinju-si Gyeongsangnam-do
Query!
Country [137]
0
0
Korea, Republic of
Query!
State/province [137]
0
0
Seongnam-si
Query!
Country [138]
0
0
Korea, Republic of
Query!
State/province [138]
0
0
Seoul
Query!
Country [139]
0
0
Mexico
Query!
State/province [139]
0
0
Cuauhtemoc
Query!
Country [140]
0
0
Mexico
Query!
State/province [140]
0
0
Guadalajara
Query!
Country [141]
0
0
Mexico
Query!
State/province [141]
0
0
Mexico City
Query!
Country [142]
0
0
Mexico
Query!
State/province [142]
0
0
Oaxaca
Query!
Country [143]
0
0
Netherlands
Query!
State/province [143]
0
0
Breda
Query!
Country [144]
0
0
Netherlands
Query!
State/province [144]
0
0
Leiden
Query!
Country [145]
0
0
Netherlands
Query!
State/province [145]
0
0
s-Hertogenbosch
Query!
Country [146]
0
0
Poland
Query!
State/province [146]
0
0
Bialystok
Query!
Country [147]
0
0
Poland
Query!
State/province [147]
0
0
Lodz
Query!
Country [148]
0
0
Poland
Query!
State/province [148]
0
0
Lublin
Query!
Country [149]
0
0
Poland
Query!
State/province [149]
0
0
Poznan
Query!
Country [150]
0
0
Poland
Query!
State/province [150]
0
0
Warszawa
Query!
Country [151]
0
0
Portugal
Query!
State/province [151]
0
0
Lisbon
Query!
Country [152]
0
0
Portugal
Query!
State/province [152]
0
0
Porto
Query!
Country [153]
0
0
Romania
Query!
State/province [153]
0
0
Cluj- Napoca
Query!
Country [154]
0
0
Romania
Query!
State/province [154]
0
0
Craiova
Query!
Country [155]
0
0
Romania
Query!
State/province [155]
0
0
Jud Timis
Query!
Country [156]
0
0
Romania
Query!
State/province [156]
0
0
Timisoara
Query!
Country [157]
0
0
Spain
Query!
State/province [157]
0
0
Barcelona
Query!
Country [158]
0
0
Spain
Query!
State/province [158]
0
0
Lleida
Query!
Country [159]
0
0
Spain
Query!
State/province [159]
0
0
Madrid
Query!
Country [160]
0
0
Spain
Query!
State/province [160]
0
0
Malaga
Query!
Country [161]
0
0
Spain
Query!
State/province [161]
0
0
Ourense
Query!
Country [162]
0
0
Spain
Query!
State/province [162]
0
0
Sevilla
Query!
Country [163]
0
0
Spain
Query!
State/province [163]
0
0
Valenica
Query!
Country [164]
0
0
Spain
Query!
State/province [164]
0
0
Zaragoza
Query!
Country [165]
0
0
Switzerland
Query!
State/province [165]
0
0
Liestal
Query!
Country [166]
0
0
Switzerland
Query!
State/province [166]
0
0
St. Gallen
Query!
Country [167]
0
0
Switzerland
Query!
State/province [167]
0
0
Thun
Query!
Country [168]
0
0
Taiwan
Query!
State/province [168]
0
0
Changhua
Query!
Country [169]
0
0
Taiwan
Query!
State/province [169]
0
0
Hsia
Query!
Country [170]
0
0
Taiwan
Query!
State/province [170]
0
0
Taichung
Query!
Country [171]
0
0
Taiwan
Query!
State/province [171]
0
0
Tainan
Query!
Country [172]
0
0
Taiwan
Query!
State/province [172]
0
0
Taipei
Query!
Country [173]
0
0
Taiwan
Query!
State/province [173]
0
0
Taoyuan
Query!
Country [174]
0
0
Thailand
Query!
State/province [174]
0
0
Bangkok
Query!
Country [175]
0
0
Thailand
Query!
State/province [175]
0
0
Chiang Mai
Query!
Country [176]
0
0
Thailand
Query!
State/province [176]
0
0
Hat Yai
Query!
Country [177]
0
0
Thailand
Query!
State/province [177]
0
0
Mueang Nonthaburi
Query!
Country [178]
0
0
Turkey
Query!
State/province [178]
0
0
Adana
Query!
Country [179]
0
0
Turkey
Query!
State/province [179]
0
0
Ankara
Query!
Country [180]
0
0
Turkey
Query!
State/province [180]
0
0
Antalya
Query!
Country [181]
0
0
Turkey
Query!
State/province [181]
0
0
Bagcilar
Query!
Country [182]
0
0
Turkey
Query!
State/province [182]
0
0
Cankaya/Ankara
Query!
Country [183]
0
0
Turkey
Query!
State/province [183]
0
0
Istanbul
Query!
Country [184]
0
0
Turkey
Query!
State/province [184]
0
0
Seyhan
Query!
Country [185]
0
0
United Kingdom
Query!
State/province [185]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Daiichi Sankyo
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
AstraZeneca
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/industry
Query!
Name [2]
0
0
Merck Sharp & Dohme LLC
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Query!
Trial website
https://clinicaltrials.gov/study/NCT05555732
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Global Clinical Leader
Query!
Address
0
0
Daiichi Sankyo
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Daiichi Sankyo Contact for Clinical Trial Information
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
908-992-6400
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF)
Query!
When will data be available (start and end dates)?
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Query!
Available to whom?
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/ourmember/daiichi-sankyo/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05555732
Download to PDF